Clinical Pharmacokinetics of α1-Antitrypsin in Homozygous PiZ Deficient Patients
A pharmacokinetic study of α1-antitrypsin (ATT) was performed in 2 groups of homozygous PiZ-deficient patients (treated and untreated) and 1 group of healthy volunteers. The distribution of the 131I-labelled protein corresponds to a 3-compartment model. The intravenously administered protein diffused quickly to the extravascular compartment where some retention occurred. No significant difference in AAT metabolism was observed between the 3 groups.
The half-life of the injected protein is slightly longer than 2.5 days. The AAT protein was not stored. These results confirm the observations collected during the clinical trials. That is, a weekly infusion is necessary to obtain stable serum AAT concentrations. Monthly infusions are unable to maintain a ‘plateau’ phase. The periodicity may be limited to every 2 weeks.
KeywordsNeutrophil Elastase Pulmonary Emphysema American Review Protein Losing Enteropathy Body Scintigraphy
Unable to display preview. Download preview PDF.
- Benet LS, Sheiner LZ. Design and optimization of dosage regiments pharmacokinetic data. In Goodman et al. (Eds) The pharmacological basis of therapeutics, pp. 1675–1737, MacMillan, New York, 1980Google Scholar
- Burrows B. A clinical trial of efficacy of antiproteolytic therapy: can it be done? American Review of Respiratory Disease 127: 542–543, 1983Google Scholar
- Carles P, Constans J, Pujazon MC, Arnaud J, Lauque D, et al. Results of a two-year substitutive treatment of PiZZ emphysema with alpha-1-antitrypsin. Presse Médicale 19: 514–519, 1990Google Scholar
- Constans J, Boneu A, Carles P, Tavera C. Deposition in the lung, liver and digestive tract of alpha-1-antitrypsin injected to PiZZ deficient patients observed after total body scintigraphy. European Respiratory Journal 1 (Suppl. 2): 2165, 1988Google Scholar
- Constans J, Burnouf TH, Arnaud J, Goudemand M. Replacement therapy in PiZZ deficiency patients by industrial concentrates: determination of the elastase and trypsin inhibitory activities. American Review of Respiratory Disease 135: A275, 1987Google Scholar
- Gadek JE, Crystal RG. Alpha-1-antitrypsin deficiency. In Stanbury et al. (Eds) The metabolic basis of inherited disease, 5th ed., pp. 1450–1467, McGraw-Hill, New York, 1983Google Scholar
- Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed., Marcel Dekker Inc., USA, 1982Google Scholar
- Laurell CB, Eriksson S. The electrophoretic alpha-1-globulin pattern of serum in alpha-1-antitrypsin deficiency. Scandinavian Journal of Clinical Investigations 15: 132–140, 1963Google Scholar
- Powers JC, Bengali ZH. Elastase inhibitors for treatment of emphesema. Approaches to synthesis and biological evaluation. Reviews of Respiratory Disease 134: 1097–1100, 1986Google Scholar
- Wewers MD, Casolaro MA, Crystal RG. Comparison of alpha-1-antitrypsin levels and anti-neutrophil elastase capacity of blood and lung in a patient with the alpha-1-antitrypsin phenotype null-null before and during alpha-1-antitrypsin augmentation therapy. American Review of Respiratory Disease 135: 539–543, 1987PubMedGoogle Scholar